This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aquestive Therapeutics (AQST) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Aquestive Therapeutics (AQST) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
The latest trading day saw Aquestive Therapeutics (AQST) settling at $1.54, representing a -1.91% change from its previous close.
Aquestive Therapeutics (AQST) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Aquestive Therapeutics (AQST) stood at $1.43, denoting a +1.42% change from the preceding trading day.
Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Aquestive Therapeutics (AQST) closed at $1.32 in the latest trading session, marking a -0.75% move from the prior day.
Aquestive Therapeutics (AQST) Stock Moves -0.71%: What You Should Know
by Zacks Equity Research
In the latest trading session, Aquestive Therapeutics (AQST) closed at $1.39, marking a -0.71% move from the previous day.
Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Aquestive Therapeutics (AQST) closed at $1.52, marking a -0.65% move from the previous day.
Aquestive (AQST) Up on Reaffirming Anaphylm Development Pathway
by Zacks Equity Research
Aquestive (AQST) stock rises 11.8% as the company intends to begin a pivotal pharmacokinetic study of Anaphylm as an oral epinephrine product candidate in the fourth quarter of 2023.
Aquestive Therapeutics (AQST) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Aquestive Therapeutics (AQST) closed the most recent trading day at $1.62, moving +0.62% from the previous trading session.
Aquestive Therapeutics (AQST) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Aquestive Therapeutics (AQST) closed at $1.66 in the latest trading session, marking no change from the prior day.
Aquestive's (AQST) Libervant Accepted for FDA Review, Stock Up
by Zacks Equity Research
Aquestive (AQST) announces FDA acceptance of a regulatory application seeking approval for Libervant to treat pediatric patients with frequent seizure activity. The stock rises 4.7% in response.
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 9.09% and 23.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Aquestive (AQST) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Aquestive's (AQST) second-quarter 2023 revenues are likely to have been driven by rising licensed product revenues.
Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Aquestive Therapeutics (AQST) closed at $1.58 in the latest trading session, marking a -1.25% move from the prior day.
Aquestive Therapeutics (AQST) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Aquestive Therapeutics (AQST) closed the most recent trading day at $1.64, moving +1.86% from the previous trading session.
Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?
by Zacks Equity Research
Here is how Aquestive Therapeutics (AQST) and HCA Healthcare (HCA) have performed compared to their sector so far this year.
Aquestive Therapeutics (AQST) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Aquestive Therapeutics (AQST) closed at $1.62 in the latest trading session, marking a +0.62% move from the prior day.
Down -31.17% in 4 Weeks, Here's Why Aquestive Therapeutics (AQST) Looks Ripe for a Turnaround
by Zacks Equity Research
Aquestive Therapeutics (AQST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Are Medical Stocks Lagging Agios Pharmaceuticals (AGIO) This Year?
by Zacks Equity Research
Here is how Agios Pharmaceuticals (AGIO) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.
Alpine Immune Sciences, Inc. (ALPN) Soars 5.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is Anebulo Pharmaceuticals (ANEB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aquestive Therapeutics (AQST) and Corvus Pharmaceuticals (CRVS) have performed compared to their sector so far this year.
Are You Looking for a Top Momentum Pick? Why Aquestive Therapeutics (AQST) is a Great Choice
by Zacks Equity Research
Does Aquestive Therapeutics (AQST) have what it takes to be a top stock pick for momentum investors? Let's find out.
Best Momentum Stocks to Buy for May 9th
by Zacks Equity Research
AQST, PLTK and WWD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 9, 2023.
New Strong Buy Stocks for May 9th
by Zacks Equity Research
SBGI, AQST, PLTK, GTX and LRMR have been added to the Zacks Rank #1 (Strong Buy) List on May 9, 2023
Aquestive Therapeutics (AQST) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 210% and 9.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?